Patents by Inventor Barbara A. Gervase

Barbara A. Gervase has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hepatitis C virus asialoglycoproteins
    Publication number: 20080318275
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Application
    Filed: March 17, 2008
    Publication date: December 25, 2008
    Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Antibodies to hepatitis C virus asialoglycoproteins
    Patent number: 7105303
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: September 12, 2006
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Antibodies to hepatitis C virus asialoglycoproteins
    Publication number: 20050089843
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Application
    Filed: October 12, 2004
    Publication date: April 28, 2005
    Inventors: Robert Ralston, Frank Marcus, Kent Thudium, Barbara Gervase, John Hall, Kim Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Hepatitis C virus asialoglycoproteins
    Publication number: 20020004048
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Application
    Filed: August 13, 2001
    Publication date: January 10, 2002
    Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Hepatitis C virus asialoglycoproteins
    Patent number: 6274148
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Grant
    Filed: May 26, 1994
    Date of Patent: August 14, 2001
    Assignee: Chiron Corporation
    Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Hepatitis C virus asialoglycoproteins
    Patent number: 6074852
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: June 13, 2000
    Assignee: Chiron Corporation
    Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Hepatitis C virus asialoglycoproteins
    Patent number: 6074846
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: June 13, 2000
    Assignee: Chiron Corporation
    Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Oui-Lim Choo, Michael Houghton, George Kuo
  • Hepatitis C virus asialoglycoproteins
    Patent number: 5942234
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: August 24, 1999
    Assignee: Chiron Corporation
    Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo